Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.67 |
| ▸ | CCR7 | P32248 | 4/20 | 0.49 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860775 | 0.88 | CXCR2 (0.66) | CXCR2CCR7 | |
| SCHEMBL3851650 | 0.88 | CXCR2 (0.66) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3853004 | 0.84 | CXCR2 (0.72) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3858985 | 0.83 | CXCR2 (0.83) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3851449 | 0.83 | CXCR2 (0.73) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3856092 | 0.82 | CXCR2 (0.80) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3857366 | 0.82 | CXCR2 (0.64) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3850892 | 0.82 | CXCR2 (0.83) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3851505 | 0.82 | CXCR2 (0.71) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3857942 | 0.81 | CXCR2 (0.68) | CXCR2CCR7CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885CCR7 369/4885CX3CR1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.